{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00030855", "CSN": null, "TRF": "ORD_1665269_01", "MRN": "44543966", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1343192", "clinicalId": "1344538", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1665269_01", "SampleName": "US1588023.01", "Version": "0", "Sample": {"FM_Id": "ORD_1665269_01", "SampleId": "US1588023.01", "BlockId": "S111-37085B", "TRFNumber": "ORD_1665269_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_06_30", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10176", "MRN": "44543966", "FullName": "\u7518\u6fb9", "FirstName": "Tan", "LastName": "Kan", "SubmittedDiagnosis": "Metastatic melanoma", "Gender": "Male", "DOB": "1959_08_12", "OrderingMD": "\u67ef\u535a\u4f38", "OrderingMDId": "109266", "Pathologist": "\u6f58\u7af6\u6210", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Adrenal Gland", "CollDate": "2022_09_20", "ReceivedDate": "2023-07-11 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Melanoma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "KIT"}, {"Gene": "BRAF"}]}, "Summaries": {"alterationCount": "13", "clinicalTrialCount": "16", "resistiveCount": "0", "sensitizingCount": "3"}, "VariantProperties": {"VariantProperty": [{"geneName": "CARD11", "isVUS": "true", "variantName": "T987M"}, {"geneName": "CBL", "isVUS": "true", "variantName": "N4Y"}, {"geneName": "EP300", "isVUS": "true", "variantName": "P308L"}, {"geneName": "FGFR3", "isVUS": "true", "variantName": "G44S"}, {"geneName": "IRS2", "isVUS": "true", "variantName": "R838C"}, {"geneName": "SETD2", "isVUS": "true", "variantName": "P194_P196del"}, {"geneName": "TP53", "isVUS": "true", "variantName": "Q52P"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "FBXW7", "Include": "true", "Alterations": {"Alteration": {"Name": "rearrangement intron 5", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "rearrangement intron 5"}}, "Interpretation": "FBXW7 encodes the F_box protein subunit of the SCF ubiquitin ligase complex, which targets proteins for degradation (Welcker and Clurman, 2008; 18094723). FBXW7 inactivation is associated with chromosomal instability and with stabilization of proto_oncogenes, such as mTOR, MYC, cyclin E, NOTCH, and JUN; FBXW7 is therefore considered a tumor suppressor (Akhoondi et al., 2007; 17909001, Welcker and Clurman, 2008; 18094723). Alterations such as seen here may disrupt FBXW7 function or expression (Welcker et al., 2013; 24298052, Welcker et al., 2007; 17298674, Strohmaier et al., 2001; 11565034, Pashkova et al., 2010; 21070969, Akhoondi et al., 2007; 17909001, O Neil et al., 2007; 17646409, Malyukova et al., 2013; 23228967, Thompson et al., 2007; 17646408). FBXW7 mutations have been reported in up to 2.8% of melanomas (cBio_Liu et al., 2019; 31792460, cBio_Hodis et al., 2012; 22817889). Loss of FBXW7 expression was reported in 13% (35/270) of primary melanomas and 22.5% (34/151) of metastatic melanomas (Cheng et al., 2013; 23381582). Increased FBXW7 expression has been reported to be associated with improved 5_year OS (P=0.047, multivariate) (Cheng et al., 2013; 23381582). An additional study found observed the same trend, but did not reach statistical significance (P=0.08, univariate) (Mozuraitiene et al., 2021; 33262829). One study demonstrated that FBXW7 inactivation was associated with resistance to anti_PD_1 antibody therapy in melanoma (Gstalder et al., 2020; 32371478). FBXW7 inactivating alterations may indicate sensitivity to mTOR inhibitors (Mao et al., 2008; 18787170, Yang et al., 2015; 25749036). Case series reported objective responses for 2 patients with FBXW7_mutated cervical squamous cell carcinoma treated with everolimus (Kulkarni et al., 2020; SGO Abstract 356).", "Include": "true", "ClinicalTrialNote": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT05125523", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT03203525", "Include": "true"}, {"nctId": "NCT05036226", "Include": "true"}, {"nctId": "NCT01582191", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "NRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "Q61R", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "35.15", "isEquivocal": "false", "name": "Q61R"}}, "Interpretation": "NRAS encodes a member of the RAS family of small GTPases that mediate transduction of growth signals. Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways (Pylayeva_Gupta et al., 2011; 21993244). NRAS alterations affecting amino acids G12, G13, G60, Q61, as well as mutations I24N, T50I, T58I, and A146T have been characterized as activating and oncogenic (Buhrman et al., 2010; 20194776, Cirstea et al., 2010; 19966803, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Janakiraman et al., 2010; 20570890, Lukman et al., 2010; 20838576, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Runtuwene et al., 2011; 21263000, Scheffzek et al., 1997; 9219684, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Gremer et al., 2011; 20949621, Altmuller et al., 2017; 28594414, Hiippala et al., 2016; 26888048). NRAS mutations have been reported in 5_33% of melanoma cases, with similar frequency in primary and metastatic samples (Hunter Shain et al., 2015; 26343386, Lee et al., 2011; 21166657, Xia et al., 2014; 24755198, Puig_Butille et al., 2013; 23362874, Smalley, 2010; 19571822, Pylayeva_Gupta et al., 2011; 21993244, Monzon and Dancey, 2012; 22419879, Platz et al., 2008; 19383313, Omholt et al., 2002; 12429636, Ekedahl et al., 2013; 23855428, Dutton_Regester et al., 2013; 23890154). Similar frequencies of NRAS mutations have been reported in cutaneous melanoma, mucosal melanoma, acral lentiginous melanoma (ALM), conjunctival melanoma, vulvar melanoma, vaginal melanoma, and melanoma of unknown primary (Lee et al., 2011; 21166657, Xia et al., 2014; 24755198, Jacob et al., 2012; 22180178, Zebary et al., 2013; 23993026, Griewank et al., 2013; 23633454, Uhara et al., 2014; 23739925, Wong et al., 2005; 15917418, Aulmann et al., 2014; 24603591, Wang et al., 2019; 31578274). Conflicting findings have been reported regarding the prognostic significance of NRAS mutation in the context of melanoma, with some studies noting significant adverse impact on clinico_pathological features as well as overall and/or melanoma_free survival (Jacob et al., 2012; 22180178, Devitt et al., 2011; 21615881, Birkland et al., 2013; 23673558, Mann et al., 2013; 22931913, Si et al., 2012; 21788131, Wang et al., 2019; 31578274), whereas other studies reported no significant impact on survival (Rutkowski et al., 2014; 24959217, Carlino et al., 2014; 24918823, Ekedahl et al., 2013; 23855428, Eqberts et al., 2014;24276025, Wu et al., 2014; 25048604, Griewank et al., 2013; 23633454). On the basis of clinical evidence in hematologic malignancies (Slosberg et al., 2018; 29765547, Ravandi et al., 2015; 26657199, Maiti et al., 2019; 30635233, Khanna et al., 2015; 26870618, Heuck et al., 2016; 26228812, Abdel_Wahab et al., 2014; 24589925, Holkova et al., 2016; 26446942) and solid tumors (Slosberg et al., 2018; 29765547, Wu et al., 2018; WCLC Abstract P1.01_97, Dummer et al., 2017; 28284557, Ascierto et al., 2013; 23414587, van Herpen et al., 2019; 30956763, van Herpen et al., 2014; 30956763), NRAS activating alterations may predict sensitivity to MEK inhibitors, such as trametinib, cobimetinib, binimetinib, and selumetinib. A Phase 3 study of the MEK inhibitor binimetinib for patients with melanoma with NRAS mutations who were previously untreated or had progressed on immunotherapy reported a significant increase in median PFS as compared with dacarbazine (2.8 vs. 1.5 months) (Dummer et al., 2017; 28284557). In a nonrandomized Phase 2 study of binimetinib for 30 patients with melanoma with NRAS mutations, 20% (6/30) had a PR and 63% (19/30) had SD, and the size of brain metastases was reduced for 2 patients treated with binimetinib (Ascierto et al., 2013; 23414587). A Phase 1 study of the ERK1/2 inhibitor ulixertinib reported PRs in 18% (3/17) and SDs in 35% (6/17) of patients with melanoma with NRAS mutations (Sullivan et al., 2018; 29247021). Early_phase trials of investigational RAF inhibitors have reported benefit for individual patients with NRAS_altered melanoma. In a Phase 1 study, patients with melanoma with NRAS mutations benefited from treatment with belvarafenib, a type_2 pan_RAF inhibitor, with PRs reported in the dose_escalation (44% [4/9]) and dose_expansion (20% [2/10]) cohorts (Yen et al., 2021; 33953400). Phase 1 studies evaluating the pan_RAF inhibitor exarafenib (Spira et al., AACR Abstract CT032) and the MEK_pan_RAF dual inhibitor avutometinib (Martinez_Garcia et al., 2012; 22761467) each reported responses for individual patients. A Phase 1a/1b trial of the RAF dimer inhibitor BGB3245 also observed PRs for 2 patients pretreated with immune checkpoint inhibitors (Schram et al., 2023; AACR Abstract CT031). Retrospective analysis of patients with melanoma treated with first_line nivolumab plus ipilimumab showed significantly improved survival for those with BRAF_mutated disease (9.9 months median PFS [mPFS] and median OS [mOS] not reached) relative to those with either NRAS_mutated disease (4.8 months mPFS and 14.2 months mOS) or disease lacking BRAF and NRAS mutations (5.3 months mPFS and 16.1 months mOS) (van Not et al., 2022; 36130145).", "Include": "true", "ClinicalTrialNote": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Selumetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients with neurofibromatosis type 1 (NF1)_associated plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors (Abdel_Wahab et al., 2014; 24589925, Ascierto et al., 2013; 23414587, Zimmer et al., 2014; 24947927, van Herpen et al., 2019; 30956763, Van Herpen et al., 2014; ESMO Abstract LBA35, Dummer et al., 2017; 28284557, Slosberg et al., 2018; 29765547, Khanna et al., 2015; 26870618, Goldinger et al., 2019; 31436845, Ravandi et al., 2015; 26657199). </p> <p><b>Supporting Data:</b> In a Phase 2 study for patients with metastatic melanoma, selumetinib monotherapy achieved an ORR of 5.8%; among patients with BRAF mutations, the ORR was 11% (5/45) (Kirkwood et al., 2012; 22048237). In a Phase 2 trial of first_line treatment of BRAF_mutated metastatic melanoma, the addition of selumetinib to dacarbazine increased PFS compared to dacarbazine plus placebo (5.6 vs 3.0 months, HR=0.63) but did not significantly improve OS (13.9 vs 10.5 months, HR 0.93, p=0.39) (Robert et al., 2013; 23735514). In a Phase 2 trial for patients with BRAF wildtype advanced melanoma, the addition of selumetinib to docetaxel did not improve median PFS compared to docetaxel plus placebo (4.2 vs 3.9 months) and was associated with lower OS (9.5 months vs 11.4 months); NRAS mutation was associated with inferior OS (HR=0.78) (Gupta et al., 2014; 24567366). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Trametinib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors (Abdel_Wahab et al., 2014; 24589925, Ascierto et al., 2013; 23414587, Zimmer et al., 2014; 24947927, van Herpen et al., 2019; 30956763, Van Herpen et al., 2014; ESMO Abstract LBA35, Dummer et al., 2017; 28284557, Slosberg et al., 2018; 29765547, Khanna et al., 2015; 26870618, Goldinger et al., 2019; 31436845, Ravandi et al., 2015; 26657199). </p> <p><b>Supporting Data:</b> One retrospective study of MEK inhibitors in NRAS_mutated melanoma reported an ORR of 23% (5/22) for pretreated patients with trametinib as a single agent (Salzmann et al., 2022; 35272084), although efficacy was limited in a Phase 1 trial of advanced melanoma (0 PRs, 29% DCR [2/7]) (Falchook et al., 2012; 22805292). A real_world study of trametinib with or without anti_PD1 antibodies in immune checkpoint inhibitor (ICI)_resistant melanoma reported PRs for 5% (1/20) of patients with NRAS_mutated disease and a median OS of 6.5 months for the cohort overall (n=22) (Pigne et al., 2023; 36919691). The combination of trametinib with paclitaxel resulted in PRs for 50% (4/8) of patients with melanoma harboring NRAS mutations (Coupe et al., 2015; 25542057). Combination approaches pairing trametinib with other agents are also under investigation in NRAS_mutated melanoma. A Phase 2 study of trametinib and the BRAF/CRAF inhibitor LXH254 reported 1 PR and a DCR of 67% (16/24) for patients with ICI_resistant disease at the expansion dose (Lebbe et al., 2022; ESMO Abstract LBA40), building on a Phase 1b trial reporting an ORR of 47% (7/15) (de Braud et al., 2022; AACR Abstract CT197). A study reported responses for 25% (1/4) of patients with the combination of trametinib and ICIs (Salzmann et al., 2022; 35272084). As a monotherapy for patients with BRAF V600E/K_mutated metastatic melanoma, trametinib improved PFS (4.9 vs. 1.5 months, HR=0.54) and median OS (15.6 vs. 11.3 months, HR=0.84) compared with patients treated with chemotherapy (Robert et al., 2019; 30690294). In a Phase 1 study, 10% (4/40) of patients with BRAF_wildtype metastatic melanoma achieved a PR (Falchook et al., 2012; 22805292). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Cobimetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Cobimetinib is a MEK inhibitor that is FDA approved to treat patients with histiocytic neoplasms. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence, activating alterations of NRAS may predict sensitivity to MEK inhibitors (Abdel_Wahab et al., 2014; 24589925, Ascierto et al., 2013; 23414587, Zimmer et al., 2014; 24947927, van Herpen et al., 2019; 30956763, Van Herpen et al., 2014; ESMO Abstract LBA35, Dummer et al., 2017; 28284557, Slosberg et al., 2018; 29765547, Khanna et al., 2015; 26870618, Goldinger et al., 2019; 31436845, Ravandi et al., 2015; 26657199). </p> <p><b>Supporting Data:</b> Significant clinical responses to various other MEK inhibitors have been documented for patients with NRAS_mutated melanoma (Ascierto et al., 2013; 23414587, Adjei et al., 2008; 18390968, Zimmer et al., 2014; 24947927, Martinez_Garcia et al., 2012; 22761467). Patients with metastatic melanoma and NRAS mutations experienced PRs (26% [5/19]) and SDs (42% [8/19]) in response to cobimetinib combined with the RAF inhibitor belvarafenib (Kim et al., 2021; ESMO Abstract 529P). A Phase 1 study of cobimetinib monotherapy in solid tumors reported 1% (1/97) CR and 6% (6/97) PR, all of which were achieved by patients with melanoma (6 with BRAF V600E) (Rosen et al., 2016; 27424159). Patients with metastatic melanoma treated with cobimetinib combined with the RAF inhibitor belvarafenib experienced PRs for those with BRAF V600 mutations (33% [3/9]) and non_V600 mutations (50% [3/6])(Kim et al., 2021; ESMO Abstract 529P). In the Phase 3 IMspire170 study, the combination of atezolizumab and cobimetinib did not improve median PFS (5.5 vs. 5.7 months), ORR (26% vs. 32%) or 6_month OS (88% vs. 87%) compared with pembrolizumab for patients with previously untreated BRAF V600 wildtype melanoma (Arance et al., 2019; ESMO Abstract LBA69). Similarly, the Phase 2 TRICOTEL trial for patients with BRAF wildtype melanoma with central nervous system metastases reported an intracranial ORR of 27% following combination treatment of atezolizumab and cobimetinib (Dummer et al., 2022; 35940183). A Phase 1b study evaluating the combination of atezolizumab and cobimetinib for the treatment of patients with solid tumors reported an ORR of 41% (9/22) in patients with melanoma, regardless of BRAF status; the 12_month PFS and OS rates were 50% and 85%, respectively (Hellman et al., 2019; 30918950). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04913285", "Include": "true"}, {"nctId": "NCT04985604", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04835805", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT05580770", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}, {"nctId": "NCT04892017", "Include": "true"}, {"nctId": "NCT05340621", "Include": "true"}, {"nctId": "NCT04720976", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ERBB4", "Include": "true", "Alterations": {"Alteration": {"Name": "E542K", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "47.69", "isEquivocal": "false", "name": "E542K"}}, "Interpretation": "ERBB4 (also known as HER4) encodes a member of the ErbB receptor tyrosine kinase family that plays a role in cell proliferation and apoptosis (Rudloff and Samuels, 2010; 20404484). Activating alterations are predicted to be oncogenic, and gain_of_function mutations have been identified throughout the gene (Kurppa et al., 2016; 26050618, Prickett et al., 2009; 19718025, Rudloff and Samuels, 2010; 20404484, Nakamura et al., 2016; 27207775). The variants N181S, V348L, P854Q, and T926M have demonstrated similar activity as wildtype ERBB4 in limited preclinical studies (Tvorogov et al., 2008; 19098003, Kurppa et al., 2016; 26050618). A single_nucleotide polymorphism in ERBB4 has been associated with increased risk of non_small cell lung cancer (NSCLC) in the Chinese Han population (Wang et al., 2021; 34106605). ERBB4 mutations have been identified in various solid tumors, including stomach (13%), salivary gland (11%, 2/18), esophageal (9%), lung (8_9%), endometrioid (6%), colorectal (5%), head and neck (5%), and gallbladder carcinomas (3.9%, 2/51), and melanoma (1.8%)(Prickett et al., 2009; 19718025, Kang et al., 2017; 27340278, Milewska et al., 2018; 29383036, Hu et al, 2021; 34620079, Li et al., 2014; 24997986, Dutton_Regester et al., 2012; 22383533). In hematological malignancies, ERBB4 mutations are rare, and have been reported at low frequency in diffuse large B_cell lymphoma (DLBCL)(2.2%_5.7%), chronic lymphocytic leukemia (CLL)(0.6_1.1%), and multiple myeloma (0.5%)(cBio_Chapuy et al., 2018; 29713087, cBio_Lohr et al., 2012; 22343534, cBio_Morin et al., 2013; 23699601, cBio_Puente et al., 2015; 26200345, cBio_Quesada et al., 2011; 22158541, cBio_Landau et al., 2015; 26466571, cBio_Lohr et al., 2014; 24434212). ERBB4 amplification has been predominantly detected in gastric tumors (67%)(Shi et al., 2012; 22606006). ERBB4 fusions have been identified infrequently in solid tumors and peripheral T_cell lymphoma, although evidence for ERBB4 fusions as driver alterations is generally limited (Schubert et al., 2021; ASCO Abstract 3091, Guenzi et al., 2021; 33816604, Nakaoku et al., 2014; 24727320, Guo et al., 2016; 26949921, Boddicker et al., 2016; 27297792). Expression of N_terminally truncated oncogenic ERBB4 variants has been reported in ALK fusion_negative anaplastic large cell lymphomas (Scarfo et al., 2016; 26463425). ERBB4 mutation correlates with poorer survival for patients with colorectal cancer (CRC)(Williams et al., 2015; 25916654). Increased ERBB4 expression has been associated with worse clinical outcomes for patients with CRC (Baiocchi et al., 2009; 19390858, Ljuslinder et al., 2009; 19443355), bone sarcoma (Merimsky et al., 2003; 12883746), esophageal squamous cell carcinoma (SCC)(Yu et al., 2018; 29729836), oral SCC (Silva et al., 2014; 24338375), metastatic Ewing sarcoma (Mendoza_Naranjo et al., 2013; 23681745), gastric cancer (Xu et al., 2018; 29620274), osteosarcoma (Huang et al., 2019; 31663373), or triple_negative breast cancer (Kim et al. 2016; 26907936). In contrast, high ERBB4 expression has been described as a positive prognostic factor in breast cancer (Witton et al., 2003; 12845624, Fuchs et al., 2006; 17201160, Wang et al., 2016; 27736797), ovarian cancer (Gilmour et al., 2001; 11280782), cervical carcinomas (Lee et al., 2005; 16157365), hormone_sensitive and castrate_resistant prostate cancer (Edwards et al., 2006; 16397033), and EGFR_negative intrahepatic cholangiocarcinoma (Yang et al., 2014; 24927194). The ERBB family kinase inhibitors afatinib and lapatinib, the EGFR inhibitors erlotinib and gefitinib, and the Bruton tyrosine kinase inhibitor ibrutinib have been shown to inhibit ERBB4 at clinically achievable concentrations (Solca et al., 2012; 22888144, Nam et al., 2011; 21306821, Davis et al., 2011; 22037378, Qiu et al., 2008; 18334220, Karaman et al., 2008; 18183025, Rauf et al., 2018; 29398709). However, whether these inhibitors would be clinically effective for patients with ERBB4 mutation is unclear. Retrospective analyses of the Phase 3 LUX_Lung 8 trial reported that patients with squamous non_small cell lung cancer (NSCLC) harboring mutations in ERBB family members exhibited long_term benefit following afatinib treatment compared with patients with ERBB_wildtype tumors; there was no difference for patients treated with erlotinib (Goss et al., 2018; 29902295, Goss et al., 2021; 34195574). A meta_analysis showed that patients with ERBB4_mutated NSCLC treated with immune checkpoint inhibitors exhibited longer PFS and OS compared with patients who had ERBB4_wildtype tumors (p=0.036 and p=0.0378)(Hu et al., 2021; 34620079).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI has been detected in 16_32% of cutaneous melanomas in several small datasets, with the majority exhibiting MSI_low (Kubecek et al., 2016; 27623135). A higher frequency of MSI (low and high) has been reported in metastatic tumors (20_77%) compared to primary tumors (2_30%) (Kubecek et al., 2016; 27372860). No association between MSI status and clinicopathological features of patients with melanoma was reported in one study (Peris et al., 1995; 7561170). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "PTPRO", "Include": "true", "Alterations": {"Alteration": {"Name": "V98fs*30", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "35.39", "isEquivocal": "false", "name": "V98fs*30"}}, "Interpretation": "PTPRO, also known as GLEPP1 , encodes a protein tyrosine phosphatase that regulates podocyte function (Wiggins et al., 1994; 7665166, Wharram et al., 2000; 11086029). In the context of cancer, PTPRO is a tumor suppressor that attenuates signaling and tumorigenesis by multiple oncogenes, through dephosphorylation and/or endocytic downregulation of these substrates (Motiwala et al., 2004; 15356345, Yu et al., 2012; 22851698, Hou et al., 2013; 22821478, Dong et al., 2017; 27345410). In the TCGA datasets, PTPRO mutation has been reported at highest frequency in lung squamous cell carcinoma (SCC, 6.2%) (cBio_Cancer Genome Atlas Research Network, 2012; 22960745), uterine corpus endometrial carcinoma (5.4%) (cBio_Cancer Genome Atlas Research Network, 2013; 23636398), and lung adenocarcinoma (3%) (Cancer Genome Atlas Research Network, 2014; 25079552), whereas homozygous deletion was most frequently identified in cases of lung (3%) (Cancer Genome Atlas Research Network, 2014; 25079552) or prostate (1.8%) (Cancer Genome Atlas Research Network, 2015; 26544944) adenocarcinoma. Hypermethylation of the PTPRO promoter is also observed in breast (Li et al., 2014; 24919593, Dong et al., 2017; 27345410, Ramaswamy et al., 2009; 19095770), hepatocellular (Hsu et al., 2013; 23533167, Motiwala et al., 2003; 14508512), colorectal (Mori et al., 2004; 15059896), esophageal squamous cell (You et al., 2012; 22099875), and lung SCC (Ming et al., 2017; 28586036), as well as in some leukemias (Motiwala et al., 2007; 17545520, Stevenson et al., 2014; 24045499). Promoter methylation significantly correlates with reduced PTPRO transcript levels (Hsu et al., 2013; 23533167, Yu et al., 2012; 22851698, Motiwala et al., 2004; 15356345, Li et al., 2014; 24919593, Dong et al., 2017; 27345410) and is associated with poor prognosis for patients with lung SCC (Ming et al., 2017; 28586036) and breast cancer (Li et al., 2014; 24919593, Huang et al., 2013; 24090193, Yu et al., 2012; 22851698); in the context of the latter, epigenetic silencing of PTPRO is an independent predictor of shorter OS for patients with HER2+ disease (Li et al., 2014; 24919593, Huang et al., 2013; 24090193). Low PTPRO expression in breast cancer is also significantly associated with shorter OS and poor prognosis (Yu et al., 2012; 22851698) and in lung SCC is an independent predictor of the latter (Ming et al., 2017; 28586036). No targeted therapies are available to address genomic alterations in PTPRO. In a preclinical study of breast cancer, PTPRO expression was suppressed by estrogen but increased by tamoxifen; upregulation of PTPRO sensitized cells to this selective estrogen modulator (Ramaswamy et al., 2009; 19095770). Low PTPRO expression has been implicated in resistance to cetuximab in patients with KRAS wild_type colorectal carcinoma (Asbagh et al., 2014; 25301722).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "04", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "04"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Johnson et al., 2016; 27671167, Goodman et al., 2017; 28835386, Eroglu et al, 2018; 29320474, Shin et al., 2017; 27903500, Riaz et al., 2017; 29033130, Cristescu et al., 2018; 30309915, Samstein et al., 2019; 30643254, Ribas et al., 2019; AACR abstract 4217, Hodi et al., 2019; AACR abstract CT037, Marabelle et al., 2020; 32919529). A large_scale genomic analysis found that various melanoma subtypes harbored median tumor mutational burdens (TMBs) between 6.3 and 14.4 Muts/Mb, and 25%_40% of cases had elevated TMBs of greater than 20 Muts/Mb (FMI_Chalmers et al., 2017; 28420421). Malignant melanoma has been reported to have a high prevalence of somatic mutations compared with other tumor types (Alexandrov et al., 2013; 23945592), with desmoplastic melanoma ranking among the highest of melanoma subtypes (median TMB of 62 Muts/Mb)(Shain et al., 2015; 26343386). Higher mutational load has been reported in NF1_mutated melanoma samples compared with BRAF_mutated, NRAS_mutated, or BRAF/NRAS/NF1_wildtype samples (Johnson et al., 2016; 27671167). Mucosal and acral melanomas have been reported to have a 5_ to 10_fold lower somatic mutation burden compared with sun_exposed melanomas (mean 2.6_2.9 muts/Mb)(Hayward et al., 2017; 28467829, Furney et al., 2013; 23620124), with one study of anorectal melanoma reporting a mean mutational burden of 0.3 muts/Mb (Yang et al., 2016; 27739435). In 1 study, elevated TMB correlated with PD_L1 positive status and increased OS in tissue specimens from patients with Stage 3 melanoma (Madore et al., 2016; 26960397). In another study, elevated tissue TMB (>20 Muts/Mb) was associated with longer PFS and OS in patients treated with anti_PD_1 or anti_PD_L1 immunotherapy as compared with patients with lower TMB (Johnson et al., 2016; 27671167). Increased TMB has also been associated with histologic stage and cumulative sun exposure (Shain et al., 2015; 26559571). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple studies of immune checkpoint inhibitors in melanoma, higher TMB has corresponded with clinical benefit from treatment with anti_PD_1 or anti_PD_L1 treatments (Hodi et al., 2019; AACR Abstract CT037, Ribas et al., 2019; AACR Abstract 4217, Cristescu et al., 2018; 30309915, Johnson et al., 2016; 27671167, Ning et al., 2022; 35355708). Increased TMB has been associated with longer PFS and OS for patients with melanoma treated with nivolumab, with studies reporting increased benefit for patients with a mutational load above 162 missense mutations per tumor (~equivalency >8 Muts/Mb as measured by this assay) (Hodi et al., 2019; AACR abstract CT037). Increased TMB (~equivalency >10.8 Muts/Mb as measured by this assay) has also been associated with longer PFS and OS for patients with melanoma treated with combination nivolumab and ipilumumab (Hodi et al., 2019; AACR abstract CT037). Improved PFS and OS of patients with melanoma treated with ipilumumab has been observed across all TMB levels (Ribas et al., 2019; AACR abstract 4217, Liu et al., 2019; 31515453).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "FBXW7", "Alteration": "rearrangement intron 5", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "rearrangement intron 5", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "rearrangement intron 5", "Title": "A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "mTOR", "Locations": "Tianjin (China)", "NCTID": "NCT05125523", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "rearrangement intron 5", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "rearrangement intron 5", "Title": "Combination Chemotherapy and Bevacizumab With the NovoTTF_100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer", "StudyPhase": "PHASE 1", "Target": "VEGFA, mTOR", "Locations": "Texas", "NCTID": "NCT03203525", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "rearrangement intron 5", "Title": "COAST Therapy in Advanced Solid Tumors and Prostate Cancer", "StudyPhase": "PHASE 1/2", "Target": "DDR2, ABL, SRC, KIT, mTOR", "Locations": "South Carolina", "NCTID": "NCT05036226", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "FBXW7", "Alteration": "rearrangement intron 5", "Title": "A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "mTOR, EGFR, SRC, RET, VEGFRs", "Locations": "Texas", "NCTID": "NCT01582191", "Note": "Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "A Study to Evaluate KIN_2787 in Subjects With BRAF Mutation Positive Solid Tumors", "StudyPhase": "PHASE 1", "Target": "BRAF, MEK", "Locations": "Taipei (Taiwan), Shanghai (China), Bengbu (China), Wuhan (China), Linyi (China), Gyeonggi_do (Korea, Republic of), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Beijing (China)", "NCTID": "NCT04913285", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRAF, MEK", "Locations": "Busan (Korea, Republic of), Seoul (Korea, Republic of), Clayton (Australia), Edegem (Belgium), Oregon, Marseille (France), Barcelona (Spain), Madrid (Spain), California", "NCTID": "NCT04985604", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS_mutant Advanced Melanoma.", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs, NRAS, PD_L1", "Locations": "Seoul (Korea, Republic of), Nedlands (Australia), Waratah (Australia), Melbourne (Australia), Oslo (Norway), Bergen (Norway), Berlin (Germany), Hamburg (Germany), W\u00fcrzburg (Germany), Mannheim (Germany)", "NCTID": "NCT04835805", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs, NRAS", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "Mirdametinib + BGB_3245 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRAF, MEK", "Locations": "Waratah (Australia), Melbourne (Australia), California, Ohio, Massachusetts, Texas, Connecticut, Pennsylvania, Florida", "NCTID": "NCT05580770", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "CRAFT: The NCT_PMO_1602 Phase II Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2", "Locations": "L\u00fcbeck (Germany), W\u00fcrzburg (Germany), Mainz (Germany), Heidelberg (Germany), T\u00fcbingen (Germany)", "NCTID": "NCT04551521", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "A Safety, Tolerability and PK Study of DCC_3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1/2", "Target": "ULK1, ULK2, MEK", "Locations": "Oregon, Massachusetts, New York, Texas, Pennsylvania", "NCTID": "NCT04892017", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "OKI_179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS_mutated Melanoma (Phase 2)", "StudyPhase": "PHASE 1/2", "Target": "HDACs, MEK", "Locations": "California, Michigan, Massachusetts, New York, Tennessee, Virginia, Texas, Georgia, Florida", "NCTID": "NCT05340621", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}, {"Gene": "NRAS", "Alteration": "Q61R", "Title": "JAB_3312 Activity in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MEK, SHP2, PD_1, EGFR, KRAS", "Locations": "Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut", "NCTID": "NCT04720976", "Note": "Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways. NRAS activating mutations or amplification may therefore sensitize tumors to inhibitors of these downstream pathways.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "18094723", "FullCitation": "Welcker M, et al. Nat. Rev. Cancer (2008) pmid: 18094723", "Include": "true"}, {"number": "1", "ReferenceId": "17909001", "FullCitation": "Akhoondi S, et al. Cancer Res. (2007) pmid: 17909001", "Include": "true"}, {"number": "2", "ReferenceId": "24298052", "FullCitation": "Welcker M, et al. Genes Dev. (2013) pmid: 24298052", "Include": "true"}, {"number": "3", "ReferenceId": "17298674", "FullCitation": "Welcker M, et al. Cell Div (2007) pmid: 17298674", "Include": "true"}, {"number": "4", "ReferenceId": "11565034", "FullCitation": "Strohmaier H, et al. Nature (2001) pmid: 11565034", "Include": "true"}, {"number": "5", "ReferenceId": "21070969", "FullCitation": "Pashkova N, et al. Mol. Cell (2010) pmid: 21070969", "Include": "true"}, {"number": "6", "ReferenceId": "17646409", "FullCitation": "O Neil J, et al. J. Exp. Med. (2007) pmid: 17646409", "Include": "true"}, {"number": "7", "ReferenceId": "23228967", "FullCitation": "Malyukova A, et al. Leukemia (2013) pmid: 23228967", "Include": "true"}, {"number": "8", "ReferenceId": "17646408", "FullCitation": "Thompson BJ, et al. J. Exp. Med. (2007) pmid: 17646408", "Include": "true"}, {"number": "9", "ReferenceId": "31792460", "FullCitation": "Liu D, et al. Nat Med (2019) pmid: 31792460", "Include": "true"}, {"number": "10", "ReferenceId": "22817889", "FullCitation": "Hodis E, et al. Cell (2012) pmid: 22817889", "Include": "true"}, {"number": "11", "ReferenceId": "23381582", "FullCitation": "Cheng Y, et al. J. Invest. Dermatol. (2013) pmid: 23381582", "Include": "true"}, {"number": "12", "ReferenceId": "33262829", "FullCitation": "Mozuraitiene J, et al. Oncol Lett (2021) pmid: 33262829", "Include": "true"}, {"number": "13", "ReferenceId": "32371478", "FullCitation": "Gstalder C, et al. Cancer Discov (2020) pmid: 32371478", "Include": "true"}, {"number": "14", "ReferenceId": "18787170", "FullCitation": "Mao JH, et al. Science (2008) pmid: 18787170", "Include": "true"}, {"number": "15", "ReferenceId": "25749036", "FullCitation": "Yang H, et al. Oncotarget (2015) pmid: 25749036", "Include": "true"}, {"number": "16", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "17", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "18", "ReferenceId": "19966803", "FullCitation": "Cirstea IC, et al. Nat. Genet. (2010) pmid: 19966803", "Include": "true"}, {"number": "19", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "20", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "21", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "22", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "23", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "24", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "25", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "26", "ReferenceId": "21263000", "FullCitation": "Runtuwene V, et al. Dis Model Mech (2011) pmid: 21263000", "Include": "true"}, {"number": "27", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "28", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "29", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "30", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "31", "ReferenceId": "28594414", "FullCitation": "Altm\u00fcller F, et al. Eur J Hum Genet (2017) pmid: 28594414", "Include": "true"}, {"number": "32", "ReferenceId": "26888048", "FullCitation": "Hiippala A, et al. Am. J. Med. Genet. A (2016) pmid: 26888048", "Include": "true"}, {"number": "33", "ReferenceId": "26343386", "FullCitation": "Shain AH, et al. Nat. Genet. (2015) pmid: 26343386", "Include": "true"}, {"number": "34", "ReferenceId": "21166657", "FullCitation": "Lee JH, et al. Br. J. Dermatol. (2011) pmid: 21166657", "Include": "true"}, {"number": "35", "ReferenceId": "24755198", "FullCitation": "Xia J, et al. Mol. Cancer Ther. (2014) pmid: 24755198", "Include": "true"}, {"number": "36", "ReferenceId": "23362874", "FullCitation": "Puig_Butill\u00e9 JA, et al. Exp. Dermatol. (2013) pmid: 23362874", "Include": "true"}, {"number": "37", "ReferenceId": "19571822", "FullCitation": "J. Invest. Dermatol. (2010) pmid: 19571822", "Include": "true"}, {"number": "38", "ReferenceId": "22419879", "FullCitation": "Monzon JG, et al. Onco Targets Ther (2012) pmid: 22419879", "Include": "true"}, {"number": "39", "ReferenceId": "19383313", "FullCitation": "Platz A, et al. Mol Oncol (2008) pmid: 19383313", "Include": "true"}, {"number": "40", "ReferenceId": "12429636", "FullCitation": "Omholt K, et al. Clin. Cancer Res. (2002) pmid: 12429636", "Include": "true"}, {"number": "41", "ReferenceId": "23855428", "FullCitation": "Ekedahl H, et al. Br. J. Dermatol. (2013) pmid: 23855428", "Include": "true"}, {"number": "42", "ReferenceId": "23890154", "FullCitation": "Dutton_Regester K, et al. Pigment Cell Melanoma Res (2013) pmid: 23890154", "Include": "true"}, {"number": "43", "ReferenceId": "22180178", "FullCitation": "Jakob JA, et al. Cancer (2012) pmid: 22180178", "Include": "true"}, {"number": "44", "ReferenceId": "23993026", "FullCitation": "Zebary A, et al. J. Dermatol. Sci. (2013) pmid: 23993026", "Include": "true"}, {"number": "45", "ReferenceId": "23633454", "FullCitation": "Griewank KG, et al. Clin. Cancer Res. (2013) pmid: 23633454", "Include": "true"}, {"number": "46", "ReferenceId": "23739925", "FullCitation": "Uhara H, et al. Int. J. Clin. Oncol. (2014) pmid: 23739925", "Include": "true"}, {"number": "47", "ReferenceId": "15917418", "FullCitation": "Wong CW, et al. J. Clin. Pathol. (2005) pmid: 15917418", "Include": "true"}, {"number": "48", "ReferenceId": "24603591", "FullCitation": "Aulmann S, et al. Mod. Pathol. (2014) pmid: 24603591", "Include": "true"}, {"number": "49", "ReferenceId": "31578274", "FullCitation": "Wang HY, et al. Oncologist (2019) pmid: 31578274", "Include": "true"}, {"number": "50", "ReferenceId": "21615881", "FullCitation": "Devitt B, et al. Pigment Cell Melanoma Res (2011) pmid: 21615881", "Include": "true"}, {"number": "51", "ReferenceId": "23673558", "FullCitation": "Birkeland E, et al. Clin. Exp. Metastasis (2013) pmid: 23673558", "Include": "true"}, {"number": "52", "ReferenceId": "22931913", "FullCitation": "Mann GJ, et al. J. Invest. Dermatol. (2013) pmid: 22931913", "Include": "true"}, {"number": "53", "ReferenceId": "21788131", "FullCitation": "Si L, et al. Eur. J. Cancer (2012) pmid: 21788131", "Include": "true"}, {"number": "54", "ReferenceId": "24959217", "FullCitation": "Rutkowski P, et al. Oncol Lett (2014) pmid: 24959217", "Include": "true"}, {"number": "55", "ReferenceId": "24918823", "FullCitation": "Carlino MS, et al. Br. J. Cancer (2014) pmid: 24918823", "Include": "true"}, {"number": "56", "ReferenceId": "24276025", "FullCitation": "Egberts F, et al. Ann. Oncol. (2014) pmid: 24276025", "Include": "true"}, {"number": "57", "ReferenceId": "25048604", "FullCitation": "Wu S, et al. Cancer Causes Control (2014) pmid: 25048604", "Include": "true"}, {"number": "58", "ReferenceId": "29765547", "FullCitation": "Slosberg ED, et al. Oncotarget (2018) pmid: 29765547", "Include": "true"}, {"number": "59", "ReferenceId": "26657199", "FullCitation": "Ravandi F, et al. Blood Cancer J (2015) pmid: 26657199", "Include": "true"}, {"number": "60", "ReferenceId": "30635233", "FullCitation": "Maiti A, et al. Clin Lymphoma Myeloma Leuk (2019) pmid: 30635233", "Include": "true"}, {"number": "61", "ReferenceId": "26870618", "FullCitation": "Khanna V, et al. Cureus (2015) pmid: 26870618", "Include": "true"}, {"number": "62", "ReferenceId": "26228812", "FullCitation": "Heuck CJ, et al. Leukemia (2016) pmid: 26228812", "Include": "true"}, {"number": "63", "ReferenceId": "24589925", "FullCitation": "Abdel_Wahab O, et al. Cancer Discov (2014) pmid: 24589925", "Include": "true"}, {"number": "64", "ReferenceId": "26446942", "FullCitation": "Holkova B, et al. Clin. Cancer Res. (2016) pmid: 26446942", "Include": "true"}, {"number": "65", "ReferenceId": "28284557", "FullCitation": "Dummer R, et al. Lancet Oncol. (2017) pmid: 28284557", "Include": "true"}, {"number": "66", "ReferenceId": "23414587", "FullCitation": "Ascierto PA, et al. Lancet Oncol. (2013) pmid: 23414587", "Include": "true"}, {"number": "67", "ReferenceId": "30956763", "FullCitation": "van Herpen CML, et al. Oncotarget (2019) pmid: 30956763", "Include": "true"}, {"number": "68", "ReferenceId": "29247021", "FullCitation": "Sullivan RJ, et al. Cancer Discov (2018) pmid: 29247021", "Include": "true"}, {"number": "69", "ReferenceId": "33953400", "FullCitation": "Yen I, et al. Nature (2021) pmid: 33953400", "Include": "true"}, {"number": "70", "ReferenceId": "22761467", "FullCitation": "Martinez_Garcia M, et al. Clin. Cancer Res. (2012) pmid: 22761467", "Include": "true"}, {"number": "71", "ReferenceId": "36130145", "FullCitation": "van Not OJ, et al. JCO Precis Oncol (2022) pmid: 36130145", "Include": "true"}, {"number": "72", "ReferenceId": "20404484", "FullCitation": "Rudloff U, et al. Cell Cycle (2010) pmid: 20404484", "Include": "true"}, {"number": "73", "ReferenceId": "26050618", "FullCitation": "Kurppa KJ, et al. Oncogene (2016) pmid: 26050618", "Include": "true"}, {"number": "74", "ReferenceId": "19718025", "FullCitation": "Prickett TD, et al. Nat. Genet. (2009) pmid: 19718025", "Include": "true"}, {"number": "75", "ReferenceId": "27207775", "FullCitation": "Nakamura Y, et al. Mol. Cancer Ther. (2016) pmid: 27207775", "Include": "true"}, {"number": "76", "ReferenceId": "19098003", "FullCitation": "Tvorogov D, et al. J. Biol. Chem. (2009) pmid: 19098003", "Include": "true"}, {"number": "77", "ReferenceId": "34106605", "FullCitation": "Wang WP, et al. Medicine (Baltimore) (2021) pmid: 34106605", "Include": "true"}, {"number": "78", "ReferenceId": "27340278", "FullCitation": "Kang H, et al. Clin. Cancer Res. (2017) pmid: 27340278", "Include": "true"}, {"number": "79", "ReferenceId": "29383036", "FullCitation": "Milewska M, et al. Ther Adv Med Oncol (2018) pmid: 29383036", "Include": "true"}, {"number": "80", "ReferenceId": "34620079", "FullCitation": "Hu X, et al. Mol Med (2021) pmid: 34620079", "Include": "true"}, {"number": "81", "ReferenceId": "24997986", "FullCitation": "Li M, et al. Nat. Genet. (2014) pmid: 24997986", "Include": "true"}, {"number": "82", "ReferenceId": "22383533", "FullCitation": "Dutton_Regester K, et al. Mol. Cancer Ther. (2012) pmid: 22383533", "Include": "true"}, {"number": "83", "ReferenceId": "29713087", "FullCitation": "Chapuy B, et al. Nat. Med. (2018) pmid: 29713087", "Include": "true"}, {"number": "84", "ReferenceId": "22343534", "FullCitation": "Lohr JG, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22343534", "Include": "true"}, {"number": "85", "ReferenceId": "23699601", "FullCitation": "Morin RD, et al. Blood (2013) pmid: 23699601", "Include": "true"}, {"number": "86", "ReferenceId": "26200345", "FullCitation": "Puente XS, et al. Nature (2015) pmid: 26200345", "Include": "true"}, {"number": "87", "ReferenceId": "22158541", "FullCitation": "Quesada V, et al. Nat. Genet. (2011) pmid: 22158541", "Include": "true"}, {"number": "88", "ReferenceId": "26466571", "FullCitation": "Landau DA, et al. Nature (2015) pmid: 26466571", "Include": "true"}, {"number": "89", "ReferenceId": "24434212", "FullCitation": "Lohr JG, et al. Cancer Cell (2014) pmid: 24434212", "Include": "true"}, {"number": "90", "ReferenceId": "22606006", "FullCitation": "Shi J, et al. Int J Mol Sci (2012) pmid: 22606006", "Include": "true"}, {"number": "91", "ReferenceId": "33816604", "FullCitation": "Guenzi E, et al. ERJ Open Res (2021) pmid: 33816604", "Include": "true"}, {"number": "92", "ReferenceId": "24727320", "FullCitation": "Nakaoku T, et al. Clin. Cancer Res. (2014) pmid: 24727320", "Include": "true"}, {"number": "93", "ReferenceId": "26949921", "FullCitation": "Guo T, et al. Int J Cancer (2016) pmid: 26949921", "Include": "true"}, {"number": "94", "ReferenceId": "27297792", "FullCitation": "Boddicker RL, et al. Blood (2016) pmid: 27297792", "Include": "true"}, {"number": "95", "ReferenceId": "26463425", "FullCitation": "Scarf\u00f2 I, et al. Blood (2016) pmid: 26463425", "Include": "true"}, {"number": "96", "ReferenceId": "25916654", "FullCitation": "Williams CS, et al. Carcinogenesis (2015) pmid: 25916654", "Include": "true"}, {"number": "97", "ReferenceId": "19390858", "FullCitation": "Baiocchi G, et al. Int J Colorectal Dis (2009) pmid: 19390858", "Include": "true"}, {"number": "98", "ReferenceId": "19443355", "FullCitation": "Ljuslinder I, et al. Anticancer Res. (2009) pmid: 19443355", "Include": "true"}, {"number": "99", "ReferenceId": "12883746", "FullCitation": "Merimsky O, et al. Oncol. Rep. () pmid: 12883746", "Include": "true"}, {"number": "100", "ReferenceId": "29729836", "FullCitation": "Yu W, et al. Pathol. Res. Pract. (2018) pmid: 29729836", "Include": "true"}, {"number": "101", "ReferenceId": "24338375", "FullCitation": "Silva SD, et al. Clin. Exp. Metastasis (2014) pmid: 24338375", "Include": "true"}, {"number": "102", "ReferenceId": "23681745", "FullCitation": "Mendoza_Naranjo A, et al. EMBO Mol Med (2013) pmid: 23681745", "Include": "true"}, {"number": "103", "ReferenceId": "29620274", "FullCitation": "Xu J, et al. Oncol Rep (2018) pmid: 29620274", "Include": "true"}, {"number": "104", "ReferenceId": "31663373", "FullCitation": "Huang Z, et al. Scand J Clin Lab Invest (2019) pmid: 31663373", "Include": "true"}, {"number": "105", "ReferenceId": "12845624", "FullCitation": "Witton CJ, et al. J. Pathol. (2003) pmid: 12845624", "Include": "true"}, {"number": "106", "ReferenceId": "17201160", "FullCitation": "Fuchs IB, et al. Anticancer Res. () pmid: 17201160", "Include": "true"}, {"number": "107", "ReferenceId": "27736797", "FullCitation": "Wang J, et al. Oncotarget (2016) pmid: 27736797", "Include": "true"}, {"number": "108", "ReferenceId": "11280782", "FullCitation": "Gilmour LM, et al. Cancer Res. (2001) pmid: 11280782", "Include": "true"}, {"number": "109", "ReferenceId": "16157365", "FullCitation": "Lee CM, et al. Gynecol. Oncol. (2005) pmid: 16157365", "Include": "true"}, {"number": "110", "ReferenceId": "16397033", "FullCitation": "Edwards J, et al. Clin. Cancer Res. (2006) pmid: 16397033", "Include": "true"}, {"number": "111", "ReferenceId": "24927194", "FullCitation": "Yang X, et al. Oncol. Rep. (2014) pmid: 24927194", "Include": "true"}, {"number": "112", "ReferenceId": "22888144", "FullCitation": "Solca F, et al. J. Pharmacol. Exp. Ther. (2012) pmid: 22888144", "Include": "true"}, {"number": "113", "ReferenceId": "21306821", "FullCitation": "Nam HJ, et al. Cancer Lett. (2011) pmid: 21306821", "Include": "true"}, {"number": "114", "ReferenceId": "22037378", "FullCitation": "Davis MI, et al. Nat. Biotechnol. (2011) pmid: 22037378", "Include": "true"}, {"number": "115", "ReferenceId": "18334220", "FullCitation": "Qiu C, et al. Structure (2008) pmid: 18334220", "Include": "true"}, {"number": "116", "ReferenceId": "18183025", "FullCitation": "Karaman MW, et al. Nat. Biotechnol. (2008) pmid: 18183025", "Include": "true"}, {"number": "117", "ReferenceId": "29398709", "FullCitation": "Rauf F, et al. Oncogene (2018) pmid: 29398709", "Include": "true"}, {"number": "118", "ReferenceId": "29902295", "FullCitation": "Goss GD, et al. JAMA Oncol (2018) pmid: 29902295", "Include": "true"}, {"number": "119", "ReferenceId": "34195574", "FullCitation": "Goss GD, et al. EClinicalMedicine (2021) pmid: 34195574", "Include": "true"}, {"number": "120", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "121", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "122", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "123", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "124", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "125", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "126", "ReferenceId": "27623135", "FullCitation": "Kube\u010dek O, et al. Melanoma Res. (2016) pmid: 27623135", "Include": "true"}, {"number": "127", "ReferenceId": "27372860", "FullCitation": "Kubecek O, et al. Med. Hypotheses (2016) pmid: 27372860", "Include": "true"}, {"number": "128", "ReferenceId": "7561170", "FullCitation": "Peris K, et al. J. Invest. Dermatol. (1995) pmid: 7561170", "Include": "true"}, {"number": "129", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "130", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "131", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "132", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "133", "ReferenceId": "7665166", "FullCitation": "Wiggins RC, et al. Genomics (1995) pmid: 7665166", "Include": "true"}, {"number": "134", "ReferenceId": "11086029", "FullCitation": "Wharram BL, et al. J. Clin. Invest. (2000) pmid: 11086029", "Include": "true"}, {"number": "135", "ReferenceId": "15356345", "FullCitation": "Motiwala T, et al. Proc. Natl. Acad. Sci. U.S.A. (2004) pmid: 15356345", "Include": "true"}, {"number": "136", "ReferenceId": "22851698", "FullCitation": "Yu M, et al. Mol. Cell. Biol. (2012) pmid: 22851698", "Include": "true"}, {"number": "137", "ReferenceId": "22821478", "FullCitation": "Hou J, et al. Hepatology (2013) pmid: 22821478", "Include": "true"}, {"number": "138", "ReferenceId": "27345410", "FullCitation": "Dong H, et al. Oncogene (2017) pmid: 27345410", "Include": "true"}, {"number": "139", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "140", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "141", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "142", "ReferenceId": "26544944", "FullCitation": "Cell (2015) pmid: 26544944", "Include": "true"}, {"number": "143", "ReferenceId": "24919593", "FullCitation": "Li SY, et al. BMC Genet. (2014) pmid: 24919593", "Include": "true"}, {"number": "144", "ReferenceId": "19095770", "FullCitation": "Ramaswamy B, et al. Mol. Endocrinol. (2009) pmid: 19095770", "Include": "true"}, {"number": "145", "ReferenceId": "23533167", "FullCitation": "Hsu SH, et al. J. Cell. Biochem. (2013) pmid: 23533167", "Include": "true"}, {"number": "146", "ReferenceId": "14508512", "FullCitation": "Motiwala T, et al. Oncogene (2003) pmid: 14508512", "Include": "true"}, {"number": "147", "ReferenceId": "15059896", "FullCitation": "Mori Y, et al. Cancer Res. (2004) pmid: 15059896", "Include": "true"}, {"number": "148", "ReferenceId": "22099875", "FullCitation": "You YJ, et al. Cancer Lett. (2012) pmid: 22099875", "Include": "true"}, {"number": "149", "ReferenceId": "28586036", "FullCitation": "Ming F, et al. Mol Med Rep (2017) pmid: 28586036", "Include": "true"}, {"number": "150", "ReferenceId": "17545520", "FullCitation": "Motiwala T, et al. Clin. Cancer Res. (2007) pmid: 17545520", "Include": "true"}, {"number": "151", "ReferenceId": "24045499", "FullCitation": "Stevenson WS, et al. Leukemia (2014) pmid: 24045499", "Include": "true"}, {"number": "152", "ReferenceId": "24090193", "FullCitation": "Huang YT, et al. J Transl Med (2013) pmid: 24090193", "Include": "true"}, {"number": "153", "ReferenceId": "25301722", "FullCitation": "Asbagh LA, et al. Oncotarget (2014) pmid: 25301722", "Include": "true"}, {"number": "154", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "155", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "156", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "157", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "158", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "159", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "160", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "161", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "162", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "163", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "164", "ReferenceId": "27671167", "FullCitation": "Johnson DB, et al. Cancer Immunol Res (2016) pmid: 27671167", "Include": "true"}, {"number": "165", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "166", "ReferenceId": "29320474", "FullCitation": "Eroglu Z, et al. Nature (2018) pmid: 29320474", "Include": "true"}, {"number": "167", "ReferenceId": "27903500", "FullCitation": "Shin DS, et al. Cancer Discov (2017) pmid: 27903500", "Include": "true"}, {"number": "168", "ReferenceId": "29033130", "FullCitation": "Riaz N, et al. Cell (2017) pmid: 29033130", "Include": "true"}, {"number": "169", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "170", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "171", "ReferenceId": "32919529", "FullCitation": "Lancet Oncol. (2020) pmid: 32919529", "Include": "true"}, {"number": "172", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "173", "ReferenceId": "23945592", "FullCitation": "Alexandrov LB, et al. Nature (2013) pmid: 23945592", "Include": "true"}, {"number": "174", "ReferenceId": "28467829", "FullCitation": "Hayward NK, et al. Nature (2017) pmid: 28467829", "Include": "true"}, {"number": "175", "ReferenceId": "23620124", "FullCitation": "Furney SJ, et al. J. Pathol. (2013) pmid: 23620124", "Include": "true"}, {"number": "176", "ReferenceId": "27739435", "FullCitation": "Yang HM, et al. Mod. Pathol. (2017) pmid: 27739435", "Include": "true"}, {"number": "177", "ReferenceId": "26960397", "FullCitation": "Madore J, et al. Clin. Cancer Res. (2016) pmid: 26960397", "Include": "true"}, {"number": "178", "ReferenceId": "26559571", "FullCitation": "Shain AH, et al. N. Engl. J. Med. (2015) pmid: 26559571", "Include": "true"}, {"number": "179", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "180", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "181", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "182", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "183", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "184", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "185", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "186", "ReferenceId": "35355708", "FullCitation": "Ning B, et al. Front Pharmacol (2022) pmid: 35355708", "Include": "true"}, {"number": "187", "ReferenceId": "31515453", "FullCitation": "Liu L, et al. Clin. Cancer Res. (2019) pmid: 31515453", "Include": "true"}, {"number": "188", "ReferenceId": "35940183", "FullCitation": "Dummer R, et al. Lancet Oncol (2022) pmid: 35940183", "Include": "true"}, {"number": "189", "ReferenceId": "30918950", "FullCitation": "Hellmann MD, et al. Ann. Oncol. (2019) pmid: 30918950", "Include": "true"}, {"number": "190", "ReferenceId": "27424159", "FullCitation": "Rosen LS, et al. Invest New Drugs (2016) pmid: 27424159", "Include": "true"}, {"number": "191", "ReferenceId": "18390968", "FullCitation": "Adjei AA, et al. J. Clin. Oncol. (2008) pmid: 18390968", "Include": "true"}, {"number": "192", "ReferenceId": "24947927", "FullCitation": "Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927", "Include": "true"}, {"number": "193", "ReferenceId": "31436845", "FullCitation": "Goldinger SM, et al. Br. J. Dermatol. (2020) pmid: 31436845", "Include": "true"}, {"number": "194", "ReferenceId": "22048237", "FullCitation": "Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237", "Include": "true"}, {"number": "195", "ReferenceId": "23735514", "FullCitation": "Robert C, et al. Lancet Oncol. (2013) pmid: 23735514", "Include": "true"}, {"number": "196", "ReferenceId": "24567366", "FullCitation": "Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366", "Include": "true"}, {"number": "197", "ReferenceId": "25344362", "FullCitation": "Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362", "Include": "true"}, {"number": "198", "ReferenceId": "30690294", "FullCitation": "Robert C, et al. Eur J Cancer (2019) pmid: 30690294", "Include": "true"}, {"number": "199", "ReferenceId": "22805292", "FullCitation": "Falchook GS, et al. Lancet Oncol. (2012) pmid: 22805292", "Include": "true"}, {"number": "200", "ReferenceId": "35272084", "FullCitation": "Salzmann M, et al. Eur J Cancer (2022) pmid: 35272084", "Include": "true"}, {"number": "201", "ReferenceId": "36919691", "FullCitation": "Pign\u00e9 T, et al. Melanoma Res (2023) pmid: 36919691", "Include": "true"}, {"number": "202", "ReferenceId": "25542057", "FullCitation": "Coupe N, et al. Eur. J. Cancer (2015) pmid: 25542057", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_07_10 15:58:22", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "772x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "4 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary melanoma", "flowcell_analysis": "2000029968", "gender": "male", "pathology_diagnosis": "Metastatic Melanoma", "percent_tumor_nuclei": "40", "pipeline_version": "v3.23.0", "purity_assessment": "82.95", "specimen": "ORD_1665269_01*US1588023.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1665269_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Adrenal Gland", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "808.85", "name": "SQ_US1588023.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4713", "cds_effect": "2960C>T", "depth": "401", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "47.13", "position": "chr7:2952980", "protein_effect": "T987M", "status": "unknown", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}, {"allele_fraction": "0.5027", "cds_effect": "2512C>T", "depth": "1096", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "50.27", "position": "chr13:110435889", "protein_effect": "R838C", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}, {"allele_fraction": "0.4859", "cds_effect": "130G>A", "depth": "601", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR3", "percent_reads": "48.59", "position": "chr4:1801001", "protein_effect": "G44S", "status": "unknown", "strand": "+", "transcript": "NM_000142", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}, {"allele_fraction": "0.4769", "cds_effect": "1624G>A", "depth": "606", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB4", "percent_reads": "47.69", "position": "chr2:212537981", "protein_effect": "E542K", "status": "known", "strand": "_", "transcript": "NM_005235", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}, {"allele_fraction": "0.5013", "cds_effect": "155A>C", "depth": "796", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "50.13", "position": "chr17:7579532", "protein_effect": "Q52P", "status": "unknown", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}, {"allele_fraction": "0.3539", "cds_effect": "293_294delTA", "depth": "681", "equivocal": "false", "functional_effect": "frameshift", "gene": "PTPRO", "percent_reads": "35.39", "position": "chr12:15637124", "protein_effect": "V98fs*30", "status": "likely", "strand": "+", "transcript": "NM_030667", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}, {"allele_fraction": "0.4358", "cds_effect": "10A>T", "depth": "335", "equivocal": "false", "functional_effect": "missense", "gene": "CBL", "percent_reads": "43.58", "position": "chr11:119077137", "protein_effect": "N4Y", "status": "unknown", "strand": "+", "transcript": "NM_005188", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}, {"allele_fraction": "0.4263", "cds_effect": "579_587delGCCTCCACC", "depth": "746", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "SETD2", "percent_reads": "42.63", "position": "chr3:47165538", "protein_effect": "P194_P196del", "status": "unknown", "strand": "_", "transcript": "NM_014159", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}, {"allele_fraction": "0.3515", "cds_effect": "182A>G", "depth": "569", "equivocal": "false", "functional_effect": "missense", "gene": "NRAS", "percent_reads": "35.15", "position": "chr1:115256529", "protein_effect": "Q61R", "status": "known", "strand": "_", "transcript": "NM_002524", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}, {"allele_fraction": "0.4774", "cds_effect": "923C>T", "depth": "576", "equivocal": "false", "functional_effect": "missense", "gene": "EP300", "percent_reads": "47.74", "position": "chr22:41523507", "protein_effect": "P308L", "status": "unknown", "strand": "+", "transcript": "NM_001429", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}]}, "copy_number_alterations": null, "rearrangements": {"rearrangement": {"allele_fraction": "0.2722", "description": "FBXW7(NM_033632) rearrangement intron 5", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "percent_reads": "27.22", "pos1": "chr4:153258808", "pos2": "chr4:153179635", "status": "likely", "supporting_read_pairs": "212", "targeted_gene": "FBXW7", "type": "truncation", "dna_evidence": {"sample": "SQ_US1588023.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "3.62", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}